RxDoctor Payments DataLook up a doctor →

Yuvraj Kumbkarni, MD

Endocrinology, Diabetes & Metabolism · Tampa, FLNPI 1720076177

Payments from drug & device makers

$188,506in general payments, 2019–2025

Across 1,781 payments — averaging $105.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Corcept Therapeutics$46K
  • Lilly USA, LLC$44K
  • Boehringer Ingelheim$28K
  • Sanofi-aventis U.S. LLC$15K
  • Xeris Pharmaceuticals, Inc.$11K
  • Intuity Medical Inc$8K
  • plus $36K from 54 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Corcept Therapeutics124$46,301
Lilly USA, LLC159$44,304
Boehringer Ingelheim86$28,273
Sanofi-aventis U.S. LLC111$14,617
Xeris Pharmaceuticals, Inc.80$11,079
Intuity Medical Inc9$7,633
AstraZeneca(2 entities)92$6,540
Novo Nordisk251$5,247
IBSA Pharma Inc.25$3,640
Medtronic(2 entities)59$3,534
Amgen(2 entities)81$2,506
AbbVie(2 entities)85$1,455
Bayer54$1,402
Mannkind Corporation48$932
Abbott44$832
Antares Pharma, Inc.45$759
Dexcom, Inc.36$727
Insulet Corporation35$659
Recordati_rare_diseases_inc.24$575
Cequr Corporation5$528
Amarin Pharma, Inc.33$524
Radius Health, Inc.19$408
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC18$374
Merck24$373
Amryt Pharma Holdings Ltd5$316
Amneal Pharmaceuticals LLC17$308
Kyowa Kirin, Inc.10$292
Tandem Diabetes Care, Inc.11$280
Ascensia Diabetes Care US Inc.5$270
Astellas Pharma US Inc12$269
Zealand Pharma US, Inc.13$248
Valeritas, Inc.11$183
Lifescan, Inc.8$177
Nevro Corp.9$172
Neurocrine Biosciences, Inc.6$165
Johnson & Johnson9$155
Ascendis Pharma Endocrinology Inc7$153
Avvisto Therapeutics, LLC8$143
Esperion Therapeutics, Inc.7$143
BETA Bionics, Inc.6$129
Senseonics, Incorporated2$124
Renalytix AI, Inc.6$123
Kowa Pharmaceuticals America, Inc.7$122
Eisai Inc.1$121
Acerus Pharmaceuticals Corporation5$118
Shire North American Group Inc4$110
Halozyme Inc6$107
Pfizer6$100
Tolmar, Inc.5$86
Aytu Biopharma, Inc.6$86
Vivus LLC7$85
Companion Medical, Inc.4$77
Ipsen Biopharmaceuticals, Inc2$70
Almatica Pharma LLC3$60
Ultragenyx Pharmaceutical Inc.2$54
Sequel Med Tech, LLC3$53
Novartis3$52
Madrigal Pharmaceuticals2$50
EUSA Pharma (US) LLC2$49
Globus Medical2$38

How this compares

$188,506 in reported general payments places this provider in the 90th percentile of 586 endocrinology, diabetes & metabolism providers in Florida.

See all endocrinology, diabetes & metabolism providers in Florida →

Medicare billing

Part B allowed, 2024
$84,427
Medicare patients
359
Services billed
1,079

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other endocrinology, diabetes & metabolism in Tampa

See the full list for Florida →

Where these figures come from

Is this you, or does something look wrong? →